Bharat Biotech Covaxin Demonstrates 78 Percent Efficacy In Treating Covid-19
The efficacy against severe COVID-19 disease was 100 per cent with an impact on reduction in hospitalizations.
The efficacy against asymptomatic COVID-19 infection was 70 per cent, suggesting decreased transmission in Covaxin recipients, it said.
HYDERABAD: Bharat Biotech-developed Covaxin demonstrated 78 percent efficacy in treating COVID-19 as per reports released by the company.
In a press release, the company stated that the overall interim clinical efficacy of 78 per cent and 100 per cent efficacy against severe COVID-19as per the phase 3 interim analysis results of the vaccine.
The efficacy against severe COVID-19 disease was 100 per cent with an impact on reduction in hospitalizations.
The efficacy against asymptomatic COVID-19 infection was 70 per cent, suggesting decreased transmission in Covaxin recipients, it said.
COVAXIN® demonstrated overall clinical efficacy of 78% and efficacy of 100% against severe COVID-19 disease in phase 3 efficacy analysis.#Phase3 #VaccineEfficacy #Covaxin@DrKrishnaElla @SuchitraElla pic.twitter.com/zRnSgLzmMb
— BharatBiotech (@BharatBiotech) April 21, 2021
Safety and Efficacy results from the final analysis will be available in June, and the final report will be submitted to a peer-reviewed publication.
Based on the achievement of the success criteria, placebo recipients have now become eligible to receive two doses of Covaxin, the release said.
The Phase 3 study enrolled 25,800 participants between 18-98 years of age, including 10 per cent over the age of 60, with analysis conducted 14 days post-second dose.
Krishna Ella, Chairman and Managing Director of Bharat Biotech said that the efficacy data against severe COVID-19 and asymptomatic infections is highly significant, as this helps reduce hospitalizations and disease transmission, respectively
Director-General of Indian Council of Medical Research, Balram Bhargava said, "I am very pleased to state that Covaxin the first indigenous COVID-19 vaccine developed by ICMR and BBIL, has shown the efficacy of 78 per cent in the second interim analysis. I am also happy to note that Covaxin works well against most variants of SARS-CoV-2.
ICMR study shows #COVAXIN neutralises against multiple variants of SARS-CoV-2 and effectively neutralises the double mutant strain as well. @MoHFW_INDIA @DeptHealthRes #IndiaFightsCOVID19 #LargestVaccineDrive pic.twitter.com/syv5T8eHuR
— ICMR (@ICMRDELHI) April 21, 2021
Also Read: Telangana To Procure 4 Lakh Vials Of Remdesivir In A Week For Govt Hospitals: KTR
